Get the Stockscreener App
7.61
0.13%
0.01
After Hours:
7.61
Aura Biosciences Inc stock is traded at $7.61, with a volume of 275.06K.
It is up +0.13% in the last 24 hours and up +4.68% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$7.60
Open:
$7.65
24h Volume:
275.06K
Relative Volume:
0.61
Market Cap:
$786.77M
Revenue:
-
Net Income/Loss:
$-106.19M
P/E Ratio:
-4.1993
EPS:
-1.8122
Net Cash Flow:
$-85.19M
1W Performance:
+2.98%
1M Performance:
+4.68%
6M Performance:
+19.28%
1Y Performance:
+29.20%
1-Day Range:
$7.52
$7.75
1-Week Range:
$7.25
$7.879
52-Week Range:
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
7.61 | 785.74M | 0 | -106.19M | -85.19M | -1.8122 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
(AURA) Volatility Zones as Tactical Triggers - Stock Traders Daily
AURA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.4% on Pre-Clinical ProgressBalance Sheet Strength - Newser
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences highlights Bel-Sar eye cancer strategy, mid-year bladder data - MSN
AURA Director Holles Acquires 2.17M Stock Options on May 20, 2026 - Meyka
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data - Yahoo Finance
Aura Biosciences grants inducement equity awards to new CEO Natalie Holles under Nasdaq rules. - Pluang
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aura Biosciences Grants Inducement Equity Awards to New CEO Natalie Holles - Quiver Quantitative
Large equity awards granted to Aura Biosciences (AURA) director Natalie Holles - Stock Titan
Press Release: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
AURA: Bel-sar shows promise for vision-preserving cancer therapy, with pivotal data expected soon - TradingView
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
TradingKey - TradingKey
AURA Stock Price and Chart — NASDAQ:AURA - TradingView
Chen Yu and TCG Crossover report combined 9.9% stake in Aura Biosciences (AURA) - Stock Titan
Aura Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Leerink Partners Maintains Aura Biosciences(AURA.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Major Investor Makes Dramatic Exit from Aura Biosciences - TipRanks
Aura Biosciences reports Q1 results, appoints new CEO - TipRanks
Aura Biosciences (NASDAQ: AURA) posts higher Q1 loss but extends cash runway - Stock Titan
Matrix Capital fund exits 6.9M Aura Biosciences (AURA) shares in open-market sale - Stock Titan
Matrix Capital exits Aura Biosciences (AURA) after 6.9M-share, $5.64 repurchase - Stock Titan
Aura Biosciences Q1 net loss widens on higher R&D costs - TradingView
Aura Biosciences 1Q Loss/Shr 50c >AURA - Moomoo
Aura Biosciences (NASDAQ: AURA) details $299M raise, cash runway and Phase 3 plans - Stock Titan
Are medical stocks lagging Aura Biosciences (AURA) this year? - MSN
What Aura Bio (AURA) revealed in previous earnings reports | Aura Bio Loss Narrower Than ExpectedCommunity Buy Signals - Newser
Aura Biosciences (AURA) Eps Diluted (TTM) - Zacks Investment Research
Aura Biosciences, Inc. Common Stock (AURA) Stock Price Today & Analysis - Gotrade
Aura Biosciences (AURA) insider Natalie Holles files initial Form 3 - Stock Titan
Norwegian Cruise Line, Aura Biosciences and other big stocks moving lower in Monday's pre-market session - MSN
Is Aura Bio (AURA) a value trap or a value play? (Momentum Fading) 2026-05-06Top Analyst Buy Signals - Newser
Aura Biosciences closes $299.4 million public offering - Investing.com UK
Aura Biosciences prices $260M stock, warrant offering - MSN
Aura Biosciences Announces $39.6 Million Public Offering of Common Stock and Pre-Funded Warrants – Underwriting Agreement with Leerink Partners, TD Securities, and Evercore Group - Minichart
Aura Biosciences Completes Major Underwritten Equity Financing - TipRanks
Aura Biosciences closes $299.4 million public offering By Investing.com - Investing.com Australia
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Aura Biosciences Prices Equity Offering, Nets $280.8 Million; Underwritten by Leerink, TD, Evercore - TradingView
Aura Biosciences (NASDAQ: AURA) boosts cash runway with $280.8M raise and buyback - Stock Titan
Aura Biosciences Closes $299.4 Million Public Offering to Advance Precision Therapies for Solid Tumors - Quiver Quantitative
Aura raises $299M as underwriters take full extra-share option - Stock Titan
Aura Biosciences Announces Closing of $299 Million Public - GlobeNewswire
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Aura Biosciences (NASDAQ: AURA) offers 39.6M shares, repurchase $39M - Stock Titan
Aura Biosciences Appoints New CEO as Phase 3 CoMpass Trial for Belzupacap Sarotalocan Nears Enrollment Completion - Minichart
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):